drugset / Trial / NCT06809426
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Evaluating the safety and antitumor efficacy of 177Lu-LNC1011
Timeline
- Start
- 2023-08-21
- Primary completion
- 2024-10-14
- Completion
- 2024-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-LNC1011 | Other / unclassified | 2775 mbq | Intravenous |